ALB and non-small cell lung carcinoma: A randomized, double‐blind, placebo controlled phase III study to investigate efficacy and safety of first‐line treatment with HLX10 + chemotherapy (carboplatin‐nanoparticle albumin bound (Nab) paclitaxel) in patients with stage IIIB/IIIC or IV NSCLC